Last reviewed by Daniel Gana, MSc, Dr. Abraham Benavides, MD, and Brent Ristow PhD, JD 02/10/2025

What Is Endocannabinoid System Dysregulation?

ECS dysregulation is a broad term referring to any imbalance in the function of endocannabinoids, cannabinoid receptors, or enzymes that synthesize and degrade endocannabinoids.

Imagine a perfectly tuned orchestra where every instrument plays in harmony, creating a flawless melody. Now, picture what happens when one section falls out of sync—chaos erupts. This is what happens when the endocannabinoid system (ECS) becomes dysregulated. Instead of maintaining balance in the body, it spirals into dysfunction, allowing diseases to thrive unchecked.

Despite its critical role in mood, immunity, metabolism, and pain perception, the ECS remains a mystery to many. Why? Because it was discovered 37 years ago and research is still catching up. Most people, including medical doctors, don’t even know this system exists. But here’s the exciting part, science is beginning to crack the code, revealing how ECS dysregulation could be at the root of countless health conditions. 

So, what happens when the ECS falls out of sync or becomes imbalanced? Why does it matter? And most importantly, can we restore its balance? Let’s dive deep into this hidden regulator of health and uncover the groundbreaking discoveries that are rewriting the future of medicine.

How is ECS Dysregulation manifested?

ECS dysregulation can manifest in several ways, including: 

• Hyperactivity Of Cannabinoid Receptors And Endocannabinoids

Endocannabinoid receptors are designed to maintain balance within the body, meaning they should neither be overactive nor underactive. When these receptors fall out of sync with their intended signals, they can trigger a cascade of disruptions that may worsen existing conditions. A deviation from this equilibrium can have widespread consequences.

ECS hyperactivity is linked to obesity, where elevated levels of anandamide overstimulate CB1 receptors, driving increased appetite and leading to weight gain. This excessive activation disrupts metabolic balance, promoting fat storage, insulin resistance, and heightened cravings for calorie-dense foods. Over time, this dysregulation can contribute to obesity-related complications, including diabetes and cardiovascular disease. 

Endocannabinoid hyperactivity has been linked to heightened inflammation, particularly in the gut. Studies show that patients with ulcerative colitis and diverticulosis exhibit significantly elevated CB2 receptor expression and increased anandamide levels in affected tissues. This excessive ECS activation, while initially a protective response, can prolong inflammation by disrupting normal immune regulation and promoting persistent immune cell activity. 

Scientists also believe hyperactivity in the ECS may contribute to the development of diabetes by promoting energy intake and storage, impairing both glucose and lipid metabolism, exerting pro-apoptotic effects in pancreatic beta cells and facilitating inflammation in pancreatic islets. 

Research suggests that ECS dysregulation is linked to various pathological conditions, including psychiatric disorders. The high concentration of CB1 receptors in brain regions involved in cognition and mood regulation such as the amygdala, cortex, and hippocampus indicates the ECS plays a critical role in emotional processing, anxiety, and depression.

Emerging evidence also suggests that disruptions in ECS signaling may contribute to schizophrenia. These disruptions could help explain why cannabis use, particularly during adolescence, is considered a significant environmental risk factor for psychotic disorders. Schizophrenia is associated with abnormalities in cannabinoid receptor function and the broader endocannabinoid network. Since THC-containing cannabis products directly interact with these receptors, their use may worsen underlying vulnerabilities in individuals predisposed to psychosis.

ECS dysfunction is also implicated in mood disorders like major depression. Reduced endocannabinoid activity may serve as a predisposing factor for depression, and enhancing ECS function is being explored as a potential therapeutic approach for mood regulation.

The ECS plays a role in regulating cell division. Dysregulation can lead to uncontrolled proliferation, a hallmark of cancer, potentially accelerating tumor growth. Research indicates that CB1 and CB2 receptors are overexpressed in certain cancers, promoting cellular changes that favor tumor progression.

The role of ECS dysregulation in various diseases is summarized in this table, published by Pacher and Kunos in 2013. 

• Impaired Endocannabinoid Production

Endocannabinoids like anandamide and 2-AG act as messengers within the ECS, ensuring balance in stress responses, pain regulation, and immune function. When production is impaired, the system cannot effectively modulate neurotransmitters, leading to chronic inflammation, heightened pain sensitivity, and mental health issues like PTSD and depression. This deficiency is often observed, imaged, and even measurable in conditions associated with clinical endocannabinoid deficiency (CED).

• Dysfunctional Enzyme Activity Leading To Excessive Degradation

The ECS relies on enzymes like FAAH and MAGL to break down endocannabinoids after they’ve completed their function. When these enzymes become overactive, they degrade endocannabinoids too quickly, leading to a deficit in ECS signaling. 

The ECS undergoes significant alterations in cancerous tissue, particularly in the regulation of anandamide and its metabolic enzymes. Research indicates that anandamide and its synthesizing enzyme, NAPE-PLD, are upregulated nearly twofold in cancer tissues, suggesting increased endocannabinoid signaling. 

However, paradoxically, FAAH (the enzyme responsible for breaking down anandamide), is also elevated, leading to higher levels of arachidonic acid, a byproduct linked to inflammation and tumor progression. Similarly, MAGL, the primary enzyme degrading 2-AG, is increased in colorectal cancer, further disrupting ECS balance and potentially contributing to tumor development and progression. 

ECS Dysregulation vs. Clinical Endocannabinoid Deficiency (CED)

While both ECS dysregulation and clinical endocannabinoid deficiency (CED) involve dysfunction in the ECS, they differ in their underlying mechanisms. The major differences between the two are summarized below:

How Whole-Plant Active-Spectrum™ Hemp Extracts Help Restore Balance

When ECS dysregulation or clinical endocannabinoid deficiency (CED) occurs, the body struggles to maintain homeostasis, leading to chronic health conditions.

Because the ECS influences so many biological functions, it has become a promising target for drug development and natural therapies. Restoring ECS balance can offer potential therapeutic benefits, making it a key focus in managing inflammatory, neurological, and metabolic disorders.

Whole-plant, full-spectrum hemp extracts – especially our Active-Spectrum™ extracts – contain a rich variety of naturally occurring cannabinoids (e.g., CBD, CBDA, CBG, CBC, etc.), terpenes, flavonoids, and other natural plant compounds that work together through the entourage and ensemble effect. This synergy enhances ECS function in ways that isolated cannabinoids such as THC or CBD alone cannot.

The combined effect of these compounds have been reported to provide the following benefits;

• Balances ECS Hyperactivity

In cases of ECS dysregulation, cannabinoid receptors and endocannabinoid may be overstimulated (e.g., obesity, diabetes and cancer). Full-spectrum hemp extracts are reported by research to provide a balanced effect, preventing excessive ECS hyperactivity and restoring balance.

• Enhances The Entourage Effect For Optimal ECS Regulation

Isolated THC or CBD may be ineffective or even counterproductive when ECS dysregulation is severe. For instance, high-dose THC dysregulates the ECS in the hypothalamus, while CBD alone lacks the full-spectrum synergy that enhances its effects. The entourage effect that comes with Active-SpectrumTM extracts ensures a more comprehensive approach to ECS modulation, enhancing therapeutic outcomes.

• Regulates Neurotransmitter Function

Many ECS-related conditions, such as anxiety, depression, and neurodegenerative diseases, involve imbalances in neurotransmitters like serotonin, dopamine, and glutamate. Terpenes like linalool and myrcene, found in full-spectrum hemp, may contribute to calming and neuroprotective effects.

Conclusion 

In a world where stress, inflammation, and chronic conditions are on the rise, supporting your endocannabinoid system is more important than ever. Our Active-Spectrum™ extracts harness the power of a proprietary blend of cannabinoids, terpenes, and flavonoids, working in perfect synergy to restore balance, activate the entourage effect, and regulate neurotransmitter function.

Why settle for isolated compounds when nature has already perfected the formula? Experience the full potential of whole-plant hemp extracts and take the first step toward optimizing your well-being.

Ready to restore balance? Try our Active-Spectrum™ extracts today!

References
–

1. DeVuono, M. V., Hrelja, K. M., Sabaziotis, L., Rajna, A., Rock, E. M., Limebeer, C. L., Mutch, D. M., & Parker, L. A. (2018). Conditioned gaping produced by high dose Δ9-tetrahydracannabinol: Dysregulation of the hypothalamic endocannabinoid system. Neuropharmacology, 141, 272–282. https://doi.org/10.1016/j.neuropharm.2018.08.039
2. Gruden, G., Barutta, F., Kunos, G., & Pacher, P. (2016). Role of the endocannabinoid system in diabetes and diabetic complications. British Journal of Pharmacology, 173(7), 1116–1127. https://doi.org/10.1111/bph.13226
3. Hasenoehrl, C., Taschler, U., Storr, M., & Schicho, R. (2016). The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease. Neurogastroenterology and Motility : The Official Journal of the European Gastrointestinal Motility Society, 28(12), 1765–1780. https://doi.org/10.1111/nmo.12931
4. Komarnytsky, S., Rathinasabapathy, T., Wagner, C., Metzger, B., Carlisle, C., Panda, C., Le Brun-Blashka, S., Troup, J. P., & Varadharaj, S. (2021). Endocannabinoid System and Its Regulation by Polyunsaturated Fatty Acids and Full Spectrum Hemp Oils. International Journal of Molecular Sciences, 22(11), Article 11. https://doi.org/10.3390/ijms22115479
5. Marzo, V. D., & Izzo, A. A. (2006). Endocannabinoid overactivity and intestinal inflammation. Gut, 55(10), 1373–1376. https://doi.org/10.1136/gut.2005.090472
6. Nuutinen, T. (2018). Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus. European Journal of Medicinal Chemistry, 157, 198–228. https://doi.org/10.1016/j.ejmech.2018.07.076
7. Pacher, P., & Kunos, G. (2013). Modulating the endocannabinoid system in human health and disease – successes and failures. https://doi.org/10.1111/febs.12260
8. Pagano, C., Navarra, G., Coppola, L., Bifulco, M., & Laezza, C. (2021). Molecular Mechanism of Cannabinoids in Cancer Progression. International Journal of Molecular Sciences, 22(7), Article 7. https://doi.org/10.3390/ijms22073680
9. Parolaro, D., Realini, N., Vigano, D., Guidali, C., & Rubino, T. (2010). The endocannabinoid system and psychiatric disorders. Experimental Neurology, 224(1), 3–14. https://doi.org/10.1016/j.expneurol.2010.03.018
10. Russo, E. B. (2016). Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and Cannabinoid Research, 1(1), 154–165. https://doi.org/10.1089/can.2016.0009
11. Vasincu, A., Rusu, R.-N., Ababei, D.-C., Neamțu, M., Arcan, O. D., Macadan, I., Beșchea Chiriac, S., Bild, W., & Bild, V. (2023). Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity. Biomedicines, 11(6), Article 6. https://doi.org/10.3390/biomedicines11061667